NCT00589056View on ClinicalTrials.gov

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Lung Cancer
Interventions
DRUG

cisplatin

DRUG

etoposide

DRUG

nelfinavir mesylate

GENETIC

protein expression analysis

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

PROCEDURE

biopsy

RADIATION

radiation therapy

Trial Locations (1)

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00589056 - Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter